Zacks Research Weighs in on STERIS plc’s Q3 2026 Earnings (NYSE:STE)

STERIS plc (NYSE:STE) – Equities researchers at Zacks Research boosted their Q3 2026 earnings per share estimates for STERIS in a research report issued on Tuesday, August 27th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.60 per share for the quarter, up from their previous forecast of $2.32. The consensus estimate for STERIS’s current full-year earnings is $9.17 per share. Zacks Research also issued estimates for STERIS’s Q1 2027 earnings at $2.45 EPS and FY2027 earnings at $10.53 EPS.

A number of other research firms also recently issued reports on STE. Piper Sandler reaffirmed a “neutral” rating and issued a $225.00 target price (up previously from $220.00) on shares of STERIS in a research report on Friday, May 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. Stephens reiterated an “overweight” rating and set a $260.00 price target on shares of STERIS in a report on Wednesday, August 7th. Needham & Company LLC restated a “hold” rating on shares of STERIS in a research note on Thursday, August 8th. Finally, StockNews.com raised STERIS from a “hold” rating to a “buy” rating in a research report on Tuesday, August 13th. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $243.60.

STERIS Trading Up 0.3 %

NYSE:STE opened at $237.71 on Friday. The stock has a market capitalization of $23.44 billion, a PE ratio of 62.23 and a beta of 0.83. STERIS has a fifty-two week low of $195.47 and a fifty-two week high of $243.37. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49. The business’s 50-day simple moving average is $228.48 and its 200-day simple moving average is $224.38.

STERIS (NYSE:STE) last issued its quarterly earnings results on Tuesday, August 6th. The medical equipment provider reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.27 billion. During the same quarter in the prior year, the firm posted $2.00 earnings per share. The firm’s revenue for the quarter was down .4% compared to the same quarter last year.

Institutional Investors Weigh In On STERIS

A number of institutional investors and hedge funds have recently bought and sold shares of STE. Cetera Investment Advisers boosted its position in STERIS by 8.2% in the second quarter. Cetera Investment Advisers now owns 13,343 shares of the medical equipment provider’s stock worth $2,930,000 after purchasing an additional 1,013 shares during the last quarter. Kimelman & Baird LLC purchased a new position in shares of STERIS in the 2nd quarter worth about $6,456,000. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of STERIS by 7.6% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 2,040 shares of the medical equipment provider’s stock worth $448,000 after buying an additional 144 shares during the last quarter. NewEdge Advisors LLC grew its position in STERIS by 22.9% during the second quarter. NewEdge Advisors LLC now owns 5,139 shares of the medical equipment provider’s stock valued at $1,128,000 after buying an additional 956 shares during the period. Finally, Nemes Rush Group LLC grew its position in STERIS by 3.1% during the second quarter. Nemes Rush Group LLC now owns 25,524 shares of the medical equipment provider’s stock valued at $5,603,000 after buying an additional 769 shares during the period. 94.69% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at STERIS

In other STERIS news, Director Christopher S. Holland sold 473 shares of STERIS stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company’s stock, valued at $139,493.76. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 1.14% of the company’s stock.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, September 5th will be issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.96%. This is a boost from STERIS’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, September 5th. STERIS’s dividend payout ratio is presently 54.45%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.